poisar

Stocks · News reference

B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Benzinga Newsdesk

B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DNLI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

    Denali Therapeutics (DNLI) shares gained 7.8% after reporting Q3 results that beat expectations, with Avlayah revenues reaching $17.8 million and nearly fivefold growth from the previous quarter. The company expects Q4 revenues between $30-32 million and plans multiple 2027 pipeline readouts including an accelerated approval filing for zafinofusp alfa. Despite strong commercial uptake and $1.01 billion in cash, the stock carries a Zacks Rank #3 (Hold) rating due to pipeline setbacks and the loss of Takeda as a partner.

    DNLIBIIBTAK